Psoriasis With Cell-derived Microparticles Clinical Trial
Official title:
The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab)
Background: Psoriasis, a common inflammatory disease, is associated with atherosclerotic
vascular diseases, including stroke, myocardial infarction, and impaired microcirculations,
among which circulating microparticles play an important role. In severe psoriasis, there
are increased endothelial- and platelet- microparticles that are reduced by TNF-α blockers
in parallel with clinical improvement. However, whether Stelara(ustekinumab) treatment would
decrease the level of microparticles remains unknown.
Objective: The investigators will evaluate the level of microparticles among normal control,
severe psoriasis before and 4 months after ustekinumab treatment.
Methods: The investigators will recruit 50 patients with severe psoriasis who received ustekinumab and 50 control subjects without psoriasis from August 2014 to July 2016. Concentrations of microparticles with expression for surface markers (Annexin V, CD31, and CD41a) will be measured in peripheral blood using flow cytometry. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment